Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Website URL
Similar Companies1000
Indalo Therapeutics
Indalo Therapeutics is a biotechnology company developing a drug for fibrotic diseases.
Sector
Subsector
Location
total rounds
total raised
Laekna Therapeutics
Laekna Therapeutics develops innovative therapies for cancer and liver diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
AmbAgon Therapeutics
AmbAgon Therapeutics develops cancer molecule therapeutics.
Sector
Subsector
Location
total rounds
total raised
Pathios Therapeutics
Pathios Therapeutics is a biotech company developing therapies for autoimmune diseases and cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 07.01.2021. Their latest investor Jianxin Capital. Their latest round Series D
The Carlyle Group
The Carlyle Group is a global investment firm in private equity.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors12
Number of lead investors
Number of investors
Jianxin Capital
Jianxin Capital is a healthcare industry risk investment fund.
Sector
Subsector
Location
count Of Investments
Greater Bay Area Homeland Development Fund
China's Greater Bay Area Homeland Development Fund has attracted participation from various groups in the country's business community.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Qiming Venture Partners
Qiming Venture Partners is a leading China-based venture capital firm that invests in technology, consumer, and healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
William Hu
William Hu is a managing partner of Qiming Venture Partners. William co-leads Qiming’s practice in healthcare sector and has been closely involved with more than 20 new ventures, some of which have become public or billion dollar market cap companies. On behalf of Qiming, he invested in Tigermed, Tellgen, AmoyDx, Rendu Bio, ET Healthcare, Vinno Medical, APT Medical, Sanyou Orthopedic, Canbridge, Ark Bio, Arrail Dental, JHT Clinics, WeDoctor, Medsci Clinical, and etc. Formerly, William served as a strategy consultant at IBM BCS, and Marketing & Sales management at several pharmaceutical companies. William holds Bachelor of Medicine from Shanghai Medical University and MBA from ENPC SH Campus.
current job
People
Founders3
Yao-Chang Xu
Dr. Yao-Chang Xu has more than 25 years of drug discovery and development experience in top pharmaceutical companies. Prior to founding Abbisko, Dr. Yao served as the General Manager of Hansoh Pharmaceutical Company. Serving as the first R&D head, he built a strong R&D team from blank and was responsible for overseeing all drug discovery programs. He successfully guided 10+ innovative programs from discovery to clinical development, spanning oncology, virology, CNS and other diseases. Prior to Hansoh, Dr. Yao served as Executive Director and Head of Chemistry at Novartis China, and Director of Chemistry at Eli Lilly in Indiana, USA. Dr. Yao obtained his Ph.D. from the University of Chicago and B.S. form Nanjing University. He is a member of the America Chemistry Society, Medicinal Chemistry, and Organic chemistry. He has published more than 50 international patents and numerous papers in peer-reviewed journals. He served as the reviewers many journals including J. Org. Chem., Org. Lett., JACS, Medicinal Chem., and Tetrahedron Lett. etc.Dr. Yao is a member of the China “Thousand Talent Program”.
current job
Yao-Chang Xu
Zhui Chen
Dr. Zhui Chen is a seasoned biologist and drug hunter with more than 10 years of drug discovery and development experience in top biopharmaceutical companies. He has participated in multiple programs from early discovery to translational research and clinical development, including the FDA-approved Bcl-2 inhibitor Venetoclax (ABT-199). Before co-founding Abbisko, Dr. Chen served as the Head of liver cancer discovery and translational research and later lung cancer discovery at Johnson & Johnson China R&D. Prior to that, he was an Investigator of epigenetic drug discovery and leader of oncology translational research at Novartis China and Senior Scientist at Abbott Lab, USA. Dr. Chen started his undergraduate study at Peking University and obtained B.S. degree from the University of Texas at Austin. He obtained his Ph.D. in Biochemistry from Duke University and then conducted his postdoctoral research at the University Of Texas Southwestern Medical Center.
current job
Zhui Chen
Hongping Yu
Dr. Hongping Yu has worked in drug discovery and development in large pharmaceutical companies for over 15 years. He has successfully delivered more than a dozen of preclinical candidates across a wide range of therapeutic areas with many advanced into clinical development. Prior to co-founding Abbisko, Dr. Yu served as the first head of chemistry at Hansoh Pharmaceutical Company, built up the chemistry team, and led the discovery of multiple drug candidates including next generation inhibitors of EGFR, FXR, NS5A/B and others. In previous positions, Dr. Yu worked as senior investigator at Novartis and research chemists at Merck. Dr. Yu obtained his Ph.D. in organic chemistry from the University of British Columbia and B.S. & M.S. from Tsinghua University. He is a member of the China “Thousand Talent Program”.
current job
Hongping Yu
Employee Profiles3
Activity
Recent News6
The graph reveals the ratio (%) of positive news articles in a chosen time range